Selective Inhibition of Lactate Influx in Cancer: An Opportunity to Augment Therapeutic Targeting
Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- *Corresponding Author:
- Ganapathy-Kanniappan S
Department of Radiology & Radiological Sciences
Johns Hopkins University School of Medicine
600 North Wolfe Street, Blalock 340, Baltimore, MD 21287, USA
Tel: + 410-502-6228
E-mail: [email protected]
Received Date: January 02, 2016; Accepted Date: February 15, 2016; Accepted Date: February 17, 2016
Citation: Ganapathy-Kanniappan S (2016) Selective Inhibition of Lactate Influx in Cancer: An Opportunity to Augment Therapeutic Targeting. J Cancer Sci Ther 8:036-037. doi: 10.4172/1948-5956.1000385
Copyright: © 2016 Ganapathy-Kanniappan S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
I read with great interest the article by Draoui et al., on a new class of inhibitors of lactate influx in cancer . The authors report characterization of a novel compound, 7-amino carboxycoumarin (7-ACC), which specifically inhibits one of the members of monocarboxylate transporters (MCTs), the MCT-1. Using the substrate mimetic, an analog of pyruvate, the authors also demonstrate that 7-ACC selectively blocks lactate-influx and does not interfere with the uptake of the mimetic thus establishing the molecular specificity of 7-ACC in the inhibition of lactate uptake.